



Age/Gender: 34YEARS/MALEBill Date: 16-Jun-2024 08:19 AMSample Type: WB EDTASample Collection: 16-Jun-2024 08:30 AMReff By: DR.P.GIRISample Received: 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 16-Jun-2024 06:22 PM

COMPLETE BLOOD PICTURE (CBP)

INVESTIGATION	RESULT	<u>UNITS</u>	NORMAL RANGE
HAEMOGRAM HAEMOGLOBIN (Method: Cell Counter)	14.5	gm/dL	13 -18
RBC Count (Method: Cell Counter)	5.3	Millions/Cumm	3.8 - 4.8
WBC Count (Method: Cell Counter)	8,300	Cells/Cumm	4,000 - 11,000
RDW	12.0	%	11.0 - 16.0
DIFFERENTIAL COUNT			
NEUTROPHILS (Method: Cell Counter)	59	%	40 - 75
LYMPHOCYTES (Method: Cell Counter)	34	%	20 - 40
EOSINOPHILS (Method: Cell Counter)	03	%	01 - 06
MONOCYTES (Method: Cell Counter)	04	%	02 - 10
BASOPHILS (Method: Cell Counter)	00	%	00 - 00
PCV (Haematocrit) (Method: Cell Counter)	43	%	35 - 45
MCV (Method: Cell Counter)	86	FL	83 - 101
MCH (Method: Cell Counter)	29	PG	27 - 32
MCHC (Method: Cell Counter)	35	%	32 - 35
PLATELET COUNT (Method: Cell Counter)	2.39	Lakhs/Cumm	1.5 - 4.5
PERIPHERAL SMEAR			
RBCs	NORMOCYTIC NORMOCHROMIC		

WBCs WITHIN NORMAL LIMITS







Age/Gender : **34YEARS/MALE**Bill Date : 16-Jun-2024 08:19 AM

Sample Type : **WB EDTA**Sample Collection : 16-Jun-2024 08:30 AM

Reff By : DR.P.GIRI Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 16-Jun-2024 06:22 PM

PLATELETS ADEQUATE

Sugessted Clinical Correlation If necesarry Kindly Discuss.

-----End of the Report-----

Authorized Signatory





Name : MR. G.MAHESH

Age/Gender 34YEARS/MALE : Citrate Blood Sample Type

Reff By : DR.P.GIRI

: Md Masud Ansari TypedBy

Bill Number

Bill Date : 16-Jun-2024 08:19 AM

Sample Collection : 16-Jun-2024 08:30 AM

: 16-Jun-2024 08:31 AM Sample Received

: 16-Jun-2024 06:22 PM Reporting Date

ERYTHROCYTE SEDIMENTATION RATE(ESR)

INVESTIGATION **RESULT UNITS NORMAL RANGE**

FIRST HOUR (Method: Westergrens)

Method: Westergren

1 - 50 YRS < 10 mm/hr 19 mm/hr 51 - 60 YRS < 12 mm/hr 61 - 70 yrs < 14 mm/hr

> 70 yrs < 30 mm/hr

-----End of the Report-----

LAB INCHARGE

Authorized Signatory





Age/Gender : **34YEARS/MALE** Bill Date : 16-Jun-2024 08:19 AM

Sample Type : WB EDTA Sample Collection : 16-Jun-2024 08:30 AM
Reff By : DR.P.GIRI Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 16-Jun-2024 06:23 PM

BLOOD GROUPING & Rh TYPING

INVESTIGATION RESULT

BLOOD GROUPING " A " (Method: Slide Agglutination)

RH TYPING POSITIVE

Method: METHOD:SLIDE/TUBE AGGLUTINATION (Forward & Reverse Grouping

Authorized Signatory

Reconfirm the Blood Group and Rh Type(DU Test)& Cross-match before blood transfusion.

-----End of the Report-----







Name : MR. G.MAHESH

Age/Gender : 34YEARS/MALE

Reff By : DR.P.GIRI

TypedBy : Md Masud Ansari

Bill Number : M2294

Bill Date : 16-Jun-2024 08:19 AM

Reporting Date : 16-Jun-2024 06:23 PM

DEPARTMENT OF RADIOLOGY

X - RAY CHEST PA VIEW

Trachea is in midline.

Both hila normal in density.

Cardiac silhouette maintained.

Both CP angles are clear.

Both lung parenchyma are normal.

Bony cage and soft tissues are normal.

IMPRESSION: NORMAL STUDY.

Suggested Clinical Correlation If necessary Kindly Discuss.

-----End of the Report-----



Dr. DIVESH SARVAIYA DMRD





Age/Gender : **34YEARS/MALE** Bill Date : 16-Jun-2024 08:19 AM

Sample Type : SERUM Sample Collection : 16-Jun-2024 08:30 AM

Reff By : DR.P.GIRI Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:15 PM

THYROID PROFILE (TFT)

INVESTIGATION	RESULT	<u>UNITS</u>	NORMAL RANGE
TOTAL TRIIODOTHYRONINE (T3) (Method: CLIA)	1.32	ng/ml	0.87 - 1.78
TOTAL THYROXINE (T4) (Method: CLIA)	6.95	ug/dL	4.82 - 11.72
THYROID STIMULATING HORMONE (TSH) (Method: CLIA)	4.10	uIU/mL	0.34 - 5.60

Pregnancy Reference Ranges for TSH:

1st Trimester : 0.10 - 2.50 2nd Trimester : 0.20 - 3.0

3rd Trimester: 0.20 - 3.0

(Ref: Guidelines of American Association for the diagnosis and management of Thyroid Disease during pregnancy and Postpartum, Thyroid, 2011,21:1-46).

Primary malfunction of the thyroid gland may result in excessive (Hyper) or below normal (Hypo) release of T3 or T4. In Addition, as thyroid function is directly affected by TSH. Diagnostically, T3 concentration in serum changes faster and more markedly than T4, the T3 level is also an exellent indicator of the ability of the thyroid to respond to both stimulatory and suppressive tests. Under conditions of strong thyroid stimulation, the T3 level offers a good. It is expecially useful in the differential diagnosis of primary (Thyroid) from secondary (Pituitary) and tertiary (Hypothalamus)hypothyroidism. In primary Hypothyroidism, TSH levels are significantly elevated, While in secondary and tertiary hypothyroidism, TSH levels are low. A TSH level between 6-12 miu/L with normal T4 may represent sbclinical or compensated Hypothyroidis. Supressed TSH may be seen in elderly patients who do not have thyrotoxcosis (Since the T3 is low or normal). TSH may also be suppressed in depression.

*A synchronous diurnal rhythm is found in serum TSH with low levels in the day time and higher levels at night. The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH Concentrations.

-----End of the Report-----







Age/Gender : **34YEARS/MALE** Bill Date : 16-Jun-2024 08:19 AM

Sample Type : SERUM Sample Collection : 16-Jun-2024 08:30 AM
Reff By : DR.P.GIRI Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:15 PM

Authorized Signatory LAB INCHARGE





: 34YEARS/MALE Age/Gender Bill Date : 16-Jun-2024 08:19 AM Sample Type : URINE : 16-Jun-2024 08:30 AM Sample Collection Reff By : DR.P.GIRI Sample Received : 16-Jun-2024 08:30 AM TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:16 PM

CUE(COMPLETE URINE EXAMINATION)

INVESTIGATION	RESULT	NORMAL RANGE
PHYSICAL EXAMINATION QUANTITY	20 ml	
COLOUR	PALE YELLOW	
APPEARANCE	SLIGHTLY TURBID	
REACTION (PH)	6.0	4.6 - 8.0
SPECIFIC GRAVITY	1.020	1.005 - 1.030
CHEMICAL EXAMINATION ALBUMIN	TRACE	NEGATIVE
SUGAR	NIL	NIL
UROBILINOGEN	NEGATIVE	NEGATIVE
BILE SALT	NEGATIVE	NEGATIVE
BILE PIGMENT	NEGATIVE	NEGATIVE
KETONE BODIES	NEGATIVE	NEGATIVE
MICROSCOPIC EXAMINATION PUS CELLS	3 - 4 / HPF	0 - 5 / HPF
RBC	NIL	NIL
EPETHILIAL CELLS	1 - 2 / HPF	0 - 5 / HPF
CRYSTALS	NIL	NIL
CASTS	NIL	NIL







: 16-Jun-2024 08:30 AM

Name : MR. G.MAHESH

Age/Gender : 34YEARS/MALE

Sample Type : URINE

Reff By : DR.P.GIRI

TypedBy : Md Masud Ansari Bill Number

Sample Received

Bill Date : 16-Jun-2024 08:19 AM

Sample Collection : 16-Jun-2024 08:30 AM

Reporting Date : 17-Jun-2024 07:16 PM

OTHERS NIL NIL

Method: Multi Reagent Strip / Chemical / Microscopy

-----End of the Report-----



Authorized Signatory







Age/Gender : **34YEARS/MALE** Bill Date : 16-Jun-2024 08:19 AM

Sample Type : SERUM Sample Collection : 16-Jun-2024 08:30 AM
Reff By : DR.P.GIRI Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:17 PM

CLINICAL BIOCHEMISTRY

RENAL FUNCTION TEST (RFT)

INVESTIGATION	RESULT	<u>UNITS</u>	NORMAL RANGE
Blood Urea (Method: Urease-GLDH)	40	mg/dl	13 - 45
Serum Creatinine (Method: Alkaline Picrate)	0.9	mg/dl	Male: 0.9 - 1.4 Female: 0.9 - 1.3
Serum Calcium (Method: Arsenazo)	10.1	mg/dl	8.6 - 10.3
Serum Uric Acid (Method: Uricase)	6.9	mg/dl	Male: 3.6 - 7.7 Female: 2.5 - 6.8
Serum Electrolytes			
Sodium (Na) (Method: Alkaline Picrate)	138	mmol/L	135 - 145
Potassium (K) (Method: I S E-Direct)	4.0	mmol/L	3.5-5.3
Chloride (CL) (Method: I S E)	100	mmol/L	98 - 107

Sugessted Clinical Correlation If necesarry Kindly Discuss.

-----End of the Report-----

Authorized Signatory









Age/Gender : **34YEARS/MALE** Bill Date : 16-Jun-2024 08:19 AM

Sample Type : **SERUM** Sample Collection : 16-Jun-2024 08:30 AM Reff By : **DR.P.GIRI** Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:18 PM

LIVER FUNCTION TEST (LFT)

INVESTIGATION	RESULT	<u>UNITS</u>	NORMAL RANGE
TOTAL BILIRUBIN (Method: Jendrassik and Grof)	0.6	mg/dl	0.4 - 1.2
DIRECT BILIRUBIN (Method: Modified Jendrassik)	0.1	mg/dl	Up to 0.25
INDIRECT BILIRUBIN (Method: Calculated)	0.5	mg/dl	up to 1
SGPT(ALT) (Method: Kinetic: IFCC)	38	U/L	Male :Upto 40 Female :Upto 31
SGOT(AST) (Method: Kinetic IFCC)	24	U/L	Male: Upto 37 Female: Upto 31
ALKALINE PHOSPHATASE(ALP) (Method: PNPP AMP Buffer)	110	U/L	Adults : 30-120 Children: 47 - 406
TOTAL PROTEINS (Method: Biuret)	7.3	gm/dl	6.4 - 8.3
ALBUMIN (Method: BCG)	4.1	gm/dl	3.8 - 4.4 gm/dL
GLOBULIN (Method: Calculated)	3.2	gm/dl	2.6 - 3.9
A/G Ratio (Method: Calculated)	1.2		1.2-2.2

Total Bilirubin reference range in case of Premature neonates is :0 - 1day: 1.0 - 8.0, 1 - 2day: 6.0 - 12.0, 3 - 5day: 10.0 - 14.0

-----End of the Report-----

Authorized Signatory





Age/Gender: 34YEARS/MALEBill Date: 16-Jun-2024 08:19 AMSample Type: Fluoride PlasmaSample Collection: 16-Jun-2024 08:30 AMReff By: DR.P.GIRISample Received: 16-Jun-2024 08:30 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:18 PM

FASTING BLOOD SUGAR (FBS)

INVESTIGATION	RESULT	<u>UNITS</u>	NORMAL RANGE
FASTING BLOOD SUGAR (Method: GOD/POD)	108	mg/dl	70 - 110
POST LUNCH BLOOD SUGAR (Method: GOD/POD)	139	mg/dl	80 - 160

NOTE:

The discordant post prandial blood glucose levels are observed in some of the conditions related to defective absorption, insufficient dietery intake, endocrine disorders, hypoglycemic drug overdose and reactive hypoglycemia etc...

Sugessted Clinical Correlation If necesarry Kindly Discuss.

-----End of the Report-----

LAB INCHARGE

Authorized Signatory





Age/Gender: 34YEARS/MALEBill Date: 16-Jun-2024 08:19 AMSample Type: WB EDTASample Collection: 16-Jun-2024 08:30 AMReff By: DR.P.GIRISample Received: 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:19 PM

Glycosylated Haemoglobin (HbA1c)

INVESTIGATION	RESULT	<u>UNITS</u>	NORMAL RANGE
GLYCATED HAEMOGLOBIN (HBA1C) (Method: HPLC)	5.8	%	Below 6.0% - Normal value 6.0 - 7.0 % Good control 7.0 - 8.0 % Fair Control 8.0 - 10.0 % Unsatisfactory Control > 10.0 % Poor Control
AVERAGE BLOOD GLUCOSE (Method: Calculated)	119.76	mg/dl	90 - 120 mg/dl - Excellent control 121 - 150 mg/dl - Good Control 151 - 180 mg/dl - Average Contro 181 - 210 mg/dl - Action Suggeste > 211 mg/dl - Panic Value.

INTERPRETATION:

- Monitor diabetic patients compliance with therapetic regime and long term blood glucose level control.
- It is useful in evaluating the initial 1 2 months of diabetic control in a newly pregnant diabetic female.
- In differentiating stress induced transient glucose intolerance from true diabetic.
- It also confirms discrepancies between blood glucose sellf monitoring results produced by the patients and actual degree of overall control.
- Increased in chronic renal failure, iron deficiency anemia, splenectomy, and alcohol.
- Decreased in shortended RBC life span in presence of HbS, HbC after transfusion, pregnancy etc.
- Average Blood Glucose value is calculated from HBA1C value and it indicates Average Blood Sugar level over past three months.

Sugessted Clinical Correlation If necesarry Kindly Discuss.

-----End of the Report-----



Authorized Signatory







Age/Gender : **34YEARS/MALE** Bill Date : 16-Jun-2024 08:19 AM

Sample Type : **SERUM** Sample Collection : 16-Jun-2024 08:30 AM Reff By : **DR.P.GIRI** Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:20 PM

LIPID PROFILE

INVESTIGATION	RESULT	<u>UNITS</u>	NORMAL RANGE
TOTAL CHOLESTROL (Method: CHOD/POD)	181	mg/dl	Desirable Level: < 200 Borderline : 200 - 239 Undesirable : Above 239
HDL CHOLESTROL (Method: DIRECT/ENZYME ASSAY)	36	mg/dl	Desirable : > 60 Optimal : 40-59 Undesirable : < 40
LDL CHOLESTROL (Method: Calculated)	123	mg/dl	Optimal : < 100 Near Optimal : 100 - 129 Borderline High : 130 - 159 High : 160 - 189 Very High : Above 190
VLDL CHOLESTROL (Method: Calculated)	22	mg/dl	< 30
TRIGLYCERIDES (Method: GPO-PAP)	111	mg/dl	Desirable Level : < 150 Borderline High : 150 - 199 High : 200 - 499 Very High : >= 500
CHOL/HDL RATIO (Method: Calculated)	5.0		Low Risk:3.3-4.4 Average Risk :4.5-7.1 Moderate Risk :7.2-11.0

*National Cholesterol Education Programme Adult Treatment Panel III Guidelines (US)

-----End of the Report-----

LAB INCHARGE

Authorized Signatory







Age/Gender : **34YEARS/MALE** Bill Date : 16-Jun-2024 08:19 AM

Sample Type : SERUM Sample Collection : 16-Jun-2024 08:30 AM
Reff By : DR.P.GIRI Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:20 PM

WIDAL

INVESTIGATION RESULT

SALMONELLA TYPHI' O ' 1 in 160 DILUTION

SALMONELLA TYPI 'H ' 1 in 80 DILUTION

SALMONELLA PARA TYPHI' AH' 1 in 20 DILUTION

SALMONELLA PARA TYPHI' BH' 1 in 20 DILUTION

BIOLOGICAL REFERENCE 1:80 and above titers considered as positive

Method: SEMI QUANTITAVE SLIDE AGGLUTINATION

Demonstration of a rise in the titer of antibodies by testing two or more serum samples is more meaningful than a single test. Sample taken late in disease instead of rise in titer, fall in titer may be seen in some cases. Agglutination more than or equal to 1:80 is significant. Immunised person or patients who had prior infection may develop anamnestic response.

-----End of the Report-----

Authorized Signatory LAB INCHARGE





Age/Gender : **34YEARS/MALE** Bill Date : 16-Jun-2024 08:19 AM

Sample Type : **SERUM** Sample Collection : 16-Jun-2024 08:30 AM

Reff By : DR.P.GIRI Sample Received : 16-Jun-2024 08:31 AM

TypedBy : Md Masud Ansari Reporting Date : 17-Jun-2024 07:21 PM

C - REACTIVE PROTEINS (CRP)

INVESTIGATION RESULT UNITS NORMAL RANGE

C – REACTIVE PROTEINS 13.6 mg/L 0.0 - 6.0 (Method: Immunoturbidimetry)

INERPRETAION POSITIVE

Note:

1. The CRP test is a sensitive indicator of inflammatory processes.

2. The determination of the CRP level can be used in therapy control

3.As with all the diagnostic methods, the final diagnosis should not be based on the result of a single test, but on a correlation of test results with other clinical findings.

4. The strength of agglutination is not indicative of the CRP concentration in the samples tested.

Please Corelate With Clinical Findings If Necessary Discuss

-----End of the Report-----

Authorized Signatory